These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guérin. Morales A; Herr H; Steinberg G; Given R; Cohen Z; Amrhein J; Kamat AM J Urol; 2015 Apr; 193(4):1135-43. PubMed ID: 25286009 [TBL] [Abstract][Full Text] [Related]
26. Long-term outcome of intravesical bacillus Calmette-Guérin therapy with maintenance for urinary bladder carcinoma in situ: About 47 cases. Sallami S; Khouni H; Ben Atta M; Abou El Makarim S; Zouari MB; Ben Rhouma S Tunis Med; 2016 Dec; 94(12):844. PubMed ID: 28994883 [TBL] [Abstract][Full Text] [Related]
27. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer. Lamm DL; DeHaven JI; Shriver J; Sarosdy MF J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691 [TBL] [Abstract][Full Text] [Related]
28. Intravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial. Pinsky CM; Camacho FJ; Kerr D; Geller NL; Klein FA; Herr HA; Whitmore WF; Oettgen HF Cancer Treat Rep; 1985 Jan; 69(1):47-53. PubMed ID: 3881177 [TBL] [Abstract][Full Text] [Related]
30. Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes. Gan C; Amery S; Chatterton K; Khan MS; Thomas K; O'Brien T J Urol; 2016 Jun; 195(6):1697-703. PubMed ID: 26845426 [TBL] [Abstract][Full Text] [Related]
31. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. Catalona WJ; Hudson MA; Gillen DP; Andriole GL; Ratliff TL J Urol; 1987 Feb; 137(2):220-4. PubMed ID: 3806806 [TBL] [Abstract][Full Text] [Related]
33. The response of patients with superficial bladder cancer to a second course of intravesical bacillus Calmette-Guerin. Bretton PR; Herr HW; Kimmel M; Whitmore WF; Laudone V; Oettgen HF; Fair WR J Urol; 1990 Apr; 143(4):710-2; discussion 712-3. PubMed ID: 2313796 [TBL] [Abstract][Full Text] [Related]
34. Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: Results from a randomized trial. Nakai Y; Anai S; Tanaka N; Chihara Y; Haramoto M; Otani T; Nakagawa Y; Hirao Y; Konishi N; Fujimoto K Int J Urol; 2016 Oct; 23(10):854-860. PubMed ID: 27416975 [TBL] [Abstract][Full Text] [Related]
35. Ureteral carcinoma in situ after successful intravesical therapy for superficial bladder tumors: incidence, possible pathogenesis and management. Herr HW; Whitmore WF J Urol; 1987 Aug; 138(2):292-4. PubMed ID: 3599241 [TBL] [Abstract][Full Text] [Related]
36. Local bacillus Calmette-Guerin therapy for superficial bladder cancer: clinical, histological and ultrastructural patterns. Rigatti P; Colombo R; Montorsi F; Centemero A; Guazzoni G; Di Girolamo V; Galli L; Trabucchi E Scand J Urol Nephrol; 1990; 24(3):191-8. PubMed ID: 2237295 [TBL] [Abstract][Full Text] [Related]
37. A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette-Guerin for superficial bladder cancer. Lamm DL; DeHaven JI; Shriver J; Crispen R; Grau D; Sarosdy MF J Urol; 1990 Jul; 144(1):65-7. PubMed ID: 2193172 [TBL] [Abstract][Full Text] [Related]
38. Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial. Hudson MA; Ratliff TL; Gillen DP; Haaff EO; Dresner SM; Catalona WJ J Urol; 1987 Aug; 138(2):295-8. PubMed ID: 3298694 [TBL] [Abstract][Full Text] [Related]
39. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480 [TBL] [Abstract][Full Text] [Related]